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ERRATUM
Erratum to: Translational Modeling in Schizophrenia: Predicting
Human Dopamine D2 Receptor Occupancy
Martin Johnson1,6 & Magdalena Kozielska1,7 & Venkatesh Pilla Reddy1,6 & An Vermeulen2 & Hugh A. Barton3 & Sarah Grimwood3 &
Rik de Greef4 & Geny M. M. Groothuis1 & Meindert Danhof5 & Johannes H. Proost1
Published online: 10 March 2016
Erratum to: Pharm Res
DOI 10.1007/s11095-015-1846-4
There occurred two errors in the abovemanuscript (Pharm
Res. 2015 Dec 30 [Epub ahead of print]). The correct infor-
mation is as follows:
1) The differential equations in Appendix 2 should read:
d Abvð Þ=dt ¼ CLbv=Vplasma
 
*Aplasma− CLbv=Vbvð Þ*Abv− CLbev=Vbvð Þ* f uplasma*Abv
þ CLbev=Vbevð Þ * f ubrain* Abev þ CLeff=Vbevð Þ * f ubrain* Abev
d Abevð Þ=dt ¼ CLbev=Vbvð Þ* f uplasma*Abv− CLbev=Vbevð Þ* f ubrain*Abev− CLeff=Vbevð Þ* f ubrain*Abev
− CLst=Vbevð Þ * f ubrain* Abev þ CLst=Vst fð Þ * f ubrain* Ast f
d Ast fð Þ=dt ¼ CLst=Vbevð Þ* f ubrain*Abev− CLst=Vst fð Þ* f ubrain*Ast f−kon* f ubrain*Ast f * Bmax−CBð Þ
þ koff * Astb
d Astbð Þ=dt ¼ kon* f ubrain* Ast f * Bmax−CBð Þ−koff * Astb
The online version of the original article can be found at http://dx.doi.org/10.
1007/s11095-015-1846-4.
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2) Table III should read:
Table III In vitro, in vivo and ex vivo
values estimates used in the human
D2RO predictive model.
Clozapine Haloperidol Olanzapine Paliperidone Quetiapine Risperidone
Fraction unbound in brain 0.011 a 0.023 b 0.034 a 0.0755 c 0.025 a 0.0699 c
Fraction unbound in
plasma
0.0300 d 0.0800 e 0.0700 m 0.226 f 0.170 e 0.100 f
Approach A: Human D2RO predictions based on in vitro information
Papp × 10−6 (cm/s) 28.3 a 28.6 a 15.7 a 16.8 g 33.0 a 19.8 g
CLbev (L/h) derived from
Papp
20.4 20.6 11.3 7.80 23.8 12.96
Efflux ratio – – – 2.10 g – 1.20 g
CLeff (L/h) based on ER – – – 8.58 – 2.59
In vitro Ki (nM) 82.0 h 0.700 h 5.10 i 2.075 e 155 h 2.175 e
koff (h
−1) 83.16 h 1.02 h 2.34 h 1.56 j,n 180.78 h 1.56 j
Approach B: Human D2RO predictions based on in vivo information
Pappcalc × 10
−6 (cm/s) – – 100 493 n – 493
CLbev (L/h) based on
Pappcalc
– – 72.2 355 n – 355
CLeff (L/h) scaled from rat – – NA 11594 – 2486
koff (h
−1) – – 3.04 k 0.671 l,n – 0.671 l
Approach C: Human D2RO predictions integrating in vitro and in vivo information
Corrected In vivo Kd (nM) – – 4.38 0.352 – 0.395
NA Not applicable
a Reference (32); b Reference (33); c Reference (34); d Reference (35); e In-house values; f Reference (36); g Reference
(37);
h Reference (38); i Reference (39); j Reference (5); k Reference (7); l Reference (8); m Reference (40); n Assumed to be
equal to risperidone
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